Sinovac Biotech Ltd Revenue Growth Rates (SVA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Sinovac Biotech Ltd  (NASDAQ: SVA)
 

SVA's Revenue Growth by Quarter and Year

Sinovac Biotech Ltd's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SVA Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December 385.98
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 385.98

SVAs Annual Revenue
Sinovac Biotech Ltd's Revenue in the fiscal year 2025 $ 385.98 millions
Sinovac Biotech Ltd's Revenue in the fiscal year 2024 $ 360.69 millions
Sinovac Biotech Ltd's Revenue in the fiscal year 2023 $ 447.75 millions
Sinovac Biotech Ltd's Revenue in the fiscal year 2022 $ 1,492.76 millions
Sinovac Biotech Ltd's Revenue in the fiscal year 2021 $ 19,374.90 millions




SVA Revenue fourth quarter 2025 Y/Y Growth Comment
Sinovac Biotech Ltd reported Revenue growth of 7.01% year on year in the fourth quarter 2025, to $ 385.98 millions, this is lower than Sinovac Biotech Ltd's recent average Revenue surge of 381.4%.

Looking into fourth quarter 2025 results within Major Pharmaceutical Preparations industry 182 other companies have achieved higher Revenue growth. While Sinovac Biotech Ltd' s Revenue increase of 7.01% ranks overall at the positon no. 3854 in the fourth quarter 2025.


SVA Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December 7.01 % -19.44 % -70.01 % -92.3 %
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   7.01 % -19.44 % -70.01 % -

Financial Statements
Sinovac Biotech Ltd's fourth quarter 2025 Revenue $ 385.98 millions SVA's Income Statement
Sinovac Biotech Ltd's fourth quarter 2024 Revenue $ 360.69 millions Quarterly SVA's Income Statement


SVA Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   7.01 % -19.44 % -70.01 % -


Back to SVA Growth rate Comparisons >> Back to SVA Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #183
Healthcare Sector #520
Overall #3854

Revenue Y/Y Growth Statistics
High Average Low
3694.36 % 381.4 % -92.3 %
(Dec 31 2021)   (Dec 31 2022)
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #183
Healthcare Sector #520
Overall #3854
Revenue Y/Y Growth Statistics
High Average Low
3694.36 % 381.4 % -92.3 %
(Dec 31 2021)   (Dec 31 2022)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Sinovac Biotech Ltd's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


SVA's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


SVA's IV. Quarter Q/Q Revenue Comment


Sinovac Biotech Ltd's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Dec 31 2021)
Cumulative Revenue 12 Months Ending $ 385.98 $ 360.69 $ 447.75 $ 1,492.76 $ 19,374.90
Y / Y Revenue Growth (TTM) 7.01 % -19.45 % -70.01 % -92.3 % 3694.36 %
Year on Year Revenue Growth Overall Ranking # 3854 # 2 # 8 # 0 # 0
Seqeuential Revenue Change (TTM) 7.01 % -19.45 % -70.01 % -92.3 % 3694.36 %
Seq. Revenue Growth (TTM) Overall Ranking # 3854 # 2 # 8 # 0 # 0


Cumulative Revenue growth Comment
Although Sinovac Biotech Ltd's Annual Revenue growth year on year were below company's average 381.4% , Revenue announced in the Dec 31 2025 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 7.01% year on year, from -19.45% in Dec 31 2024.

In the Healthcare sector 519 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2 to 3854.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 183
Healthcare Sector # 520
Overall # 3854

Revenue TTM Y/Y Growth Statistics
High Average Low
3694.36 %
 381.4 %
-92.3 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 183
Sector # 520
S&P 500 # 3854
Cumulative Revenue growth Comment
Although Sinovac Biotech Ltd's Annual Revenue growth year on year were below company's average 381.4% , Revenue announced in the Dec 31 2025 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 7.01% year on year, from -19.45% in Dec 31 2024.

In the Healthcare sector 519 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2 to 3854.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 183
Healthcare Sector # 520
Overall # 3854

Revenue TTM Y/Y Growth Statistics
High Average Low
3694.36 %
381.4 %
-92.3 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 183
Sector # 520
S&P 500 # 3854




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
SVA's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Dec 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2025
Elanco Animal Health Incorporated12.16%$ 12.157 millions
Livanova Plc11.62%$ 11.618 millions
Amneal Pharmaceuticals Inc 11.59%$ 11.591 millions
Karyopharm Therapeutics Inc 11.58%$ 11.581 millions
Escalon Medical Corp 11.51%$ 11.515 millions
Stryker Corp11.42%$ 11.420 millions
Warby Parker Inc 11.41%$ 11.409 millions
Sight Sciences Inc 11.38%$ 11.385 millions
Novo Nordisk A11.14%$ 11.144 millions
Pro dex Inc 11.14%$ 11.136 millions
Corcept Therapeutics Inc11.12%$ 11.125 millions
Resmed Inc 11.02%$ 11.022 millions
Agape Atp Corporation10.94%$ 10.939 millions
Zimmer Biomet Holdings Inc 10.90%$ 10.899 millions
Merit Medical Systems Inc10.75%$ 10.748 millions
Iqvia Holdings Inc 10.26%$ 10.258 millions
Biotricity Inc 10.19%$ 10.188 millions
Jazz Pharmaceuticals Plc10.09%$ 10.086 millions
Abbvie Inc 10.04%$ 10.038 millions
Encompass Health Corporation9.94%$ 9.936 millions
Davita Inc 9.87%$ 9.868 millions
Bausch and Lomb Corp9.77%$ 9.766 millions
Enanta Pharmaceuticals Inc9.76%$ 9.765 millions
Aquestive Therapeutics Inc 9.67%$ 9.674 millions
Zomedica Corp 9.67%$ 9.667 millions
Novartis Ag9.57%$ 9.574 millions
Vertex Pharmaceuticals Inc9.55%$ 9.547 millions
Procept Biorobotics Corporation9.53%$ 9.532 millions
Acadia Pharmaceuticals Inc 9.39%$ 9.394 millions
Bausch Health Companies Inc 9.26%$ 9.261 millions


About Sinovac Biotech Ltd Revenue Growth Rates (SVA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Sinovac Biotech Ltd (CIK 1084201).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-258534
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Sinovac Biotech Ltd’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.